Skip to main content

Table 2 Diagnosis and extent of cancer in the Safety population (N = 32) at study entry

From: Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: A phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

 

No. of patients

% of Safety population

Clinical tumor categories

  

T2*

23

71.9

T3

5

15.6

T4a

1

3.1

T4b

3

9.4

Primary tumor histology

  

Ductal

19

59.4

Invasive lobular/variant

8/1

25.0/3.1

Other/missing

3/1

9.4/3.1

Tumor grade

  

Well/moderately/poorly differentiated

3/16/2

9.4/50.0/6.3

Missing

11

34.4

Positive receptor status

  

Estrogen/progesterone/either

31/25/32

96.9/78.1/100.0

  1. * only if ineligible for breast-conserving surgery